EpicentRx technologies work through the simultaneous modulation of multiple epigenetic targets with tremendous potential to treat multiple disorders including cancer.
EpicentRx is a Silicon Valley-based discovery and development company that has developed a comprehensive portfolio of proprietary NASA-derived molecules with novel mechanisms of action.
RRx-001 has the potential to resensitize tumors to failed chemotherapies, turning back the clock and resetting the cancer timeline.
EpicentRx has developed a platform called VIMMUNE™ of tumor-targeted replication-competent adenoviruses armed with immunostimulatory transgenes to induce cytotoxic T lymphocyte responses.
Emerging research places epigenetic inhibitors like RRx-001 at the intersection between epigenetics and anti-tumor immunity through the activation of a class of proteins called interferons, a type of cytokine, which stimulates the immune system to kill cancer cells.
RRx-001 potential sensitization and resensitization to immunotherapy (e.g. anti-PD-1).